The UK coronavirus vaccine has taken a major step forwards, after scientists revealed plans for mass-production if trials are successul.
The University of Oxford has partnered with pharmaceutical giant AstraZenenca for the development, manufacture and large-scale distribution of the Covid-19 vaccine candidate that is currently being trialled in the UK.
The agreement was announced on Thursday, with the details set to be finalised in the coming weeks.
The move will allow for rapid vaccination around the world if the candidate proves to be effective, the university said.
Human trials of the vaccine developed by the University’s Jenner Institute began last week, with hundreds of people volunteering to be part of the study which received £20 million in Government funding.
Professor Sir John Bell, Regius Professor of Medicine at Oxford University described the partnership with AstraZeneca as a “major force in the struggle against pandemics” for the foreseeable future.